The Cutaneous Lupus Erythematosus Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).
Learn More On The Cutaneous Lupus Erythematosus Market:
https://www.thebusinessresearchcompany.com/report/cutaneous-lupus-erythematosus-global-market-report
According to The Business Research Company’s Cutaneous Lupus Erythematosus Global Market Report 2024, The cutaneous lupus erythematosus market size has grown rapidly in recent years. It will grow from $2.01 billion in 2023 to $2.24 billion in 2024 at a compound annual growth rate (CAGR) of 11.7%. The growth in the historic period can be attributed to government and private funding, the expansion of healthcare infrastructure, increased awareness and education, enhanced support systems for patients, and the and the rising prevalence of autoimmune disorders.
The cutaneous lupus erythematosus market size is expected to see rapid growth in the next few years. It will grow to $3.5 billion in 2028 at a compound annual growth rate (CAGR) of 11.8%. The growth in the forecast period can be attributed to increasing research and development investments, regulatory approvals and support, an aging population, enhanced patient education and awareness campaigns, and global market expansion. Major trends in the forecast period include the expansion of telemedicine, enhanced patient monitoring and management, technological integration in healthcare, the growth of personalized and precision medicine, and the and the use of genomic and proteomic technologies.
The rising prevalence of skin infections is expected to propel the growth of the cutaneous lupus erythematosus (CLE) market going forward. Skin infections are conditions in which microorganisms, such as bacteria, fungi, or viruses, invade and multiply within the skin, leading to various symptoms and discomfort. Skin infections activate the immune system, leading to an inflammatory response to fight off the infection. In individuals with CLE, this heightened immune response can target the skin cells, worsening the symptoms of CLE. For instance, in September 2022, according to the UK Health Security Agency (UKHSA), a UK-based national executive agency, the percentage of Methicillin-resistant Staphylococcus aureus (MRSA) cases caused by skin and soft tissue infections increased to 33.7% in 2022 from 2021. Moreover, MRSA cases increased by 25.7% in the financial year from April 2020 to March 2021. Therefore, the rising prevalence of skin infections will drive the growth of the cutaneous lupus erythematosus market.
Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample.aspx?id=18328&type=smp
The cutaneous lupus erythematosus market covered in this report is segmented –
1) By Type: Acute, Subacute, Intermittent, Chronic
2) By Drug Class: Retinoids, Corticosteroids, Immunosuppressants, Antimalarial Drugs, Other Drug Classes
3) By Route Of Administration: Oral, Injections, Topical, Other Routes Of Administration
4) By End-Users: Hospitals, Specialty Clinics, Homecare, Other End-Users
Major companies operating in the cutaneous lupus erythematosus market are innovating monoclonal antibody treatment to enhance treatment efficacy, improve patient outcomes, and provide more convenient and targeted therapies. Monoclonal antibody treatment involves using identical antibodies that are designed to target specific proteins or cells involved in disease processes to treat various conditions, including autoimmune disorders such as lupus. For instance, in August 2021, AstraZeneca Plc, a UK-based pharmaceutical and biotechnology company, developed Saphnelo (anifrolumab), approved by the Food and Drug Administration (FDA) for treating adults with moderate to severe systemic lupus erythematosus (SLE) receiving standard therapy. It represents a pioneering type I interferon receptor antibody that functions by binding to subunit 1 of the type I interferon (IFN) receptor, effectively inhibiting type I IFN activity. The heightened signaling of type I IFN correlates with escalated disease activity and severity. Saphnelo is undergoing regulatory review for lupus erythematosus in the European Union (EU) and Japan. A Phase III trial utilizing subcutaneous delivery has commenced, with further Phase III trials slated for lupus nephritis and cutaneous lupus erythematosus.
The cutaneous lupus erythematosus market report table of contents includes:
1. Executive Summary
2. Cutaneous Lupus Erythematosus Market Characteristics
3. Cutaneous Lupus Erythematosus Market Trends And Strategies
4. Cutaneous Lupus Erythematosus Market – Macro Economic Scenario
5. Global Cutaneous Lupus Erythematosus Market Size and Growth
…
32. Global Cutaneous Lupus Erythematosus Market Competitive Benchmarking
33. Global Cutaneous Lupus Erythematosus Market Competitive Dashboard
34. Key Mergers And Acquisitions In The Cutaneous Lupus Erythematosus Market
35. Cutaneous Lupus Erythematosus Market Future Outlook and Potential Analysis
36. Appendix
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
